Skip to content
akaturk Academic measurement
  1. Ana Dal Sağlık Bilimleri Temel Alanı
  2. Yan Dal Tıbbi Onkoloji (İç Hastalıkları)
Academic summary YÖKSİS and OpenAlex counted separately.
Articles 161
YÖKSİS161 OpenAlex0
Projects 0
Books 0
Proceedings 10

Citation impact

OpenAlex YÖKSİS articles matched in OpenAlex: 147
h-index 19 Percentile in Türkiye: 97 #11 of 1,071 at their university by h-index
i10-index
32
Total citations
16,120
Top 0.1% in Türkiye
Per article
109.7
FWCI
6.46
1.00 = world average
World top 1%
7
World top 10%
12

h-index and citations are computed from the citation counts of this academic’s YÖKSİS articles matched in OpenAlex (not Google Scholar, WoS or Scopus). Unmatched articles are not included.

Field ranking

YÖKSİS ?

Index quartiles

?
Scopus (SJR) 157
  • Q1 88 %56.1
  • Q2 44 %28.0
  • Q3 23 %14.6
  • Q4 2 %1.3
WoS (JCR) 159
  • Q1 56 %35.2
  • Q2 28 %17.6
  • Q3 27 %17.0
  • Q4 48 %30.2
TR Index 4 articles
OpenAlex citation percentile
Top 1%7
Top 10%12
Avg · n 138 %48.1
Other counts

Scopus (SJR)

  • YÖKSİS rows 163

WoS (JCR)

  • YÖKSİS rows 165

Articles

Articles with YÖKSİS and OpenAlex source split; narrow by quartile or TR Index.

161articles

Journals with publications

64 journals

Narrow down

Scopus (SJR)
WoS (JCR)
TR Index

Article filter applied. Journal filter: New England Journal of Medicine Clear filter ×

Article list

7 / 161 articles

  1. 2022 Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer New England Journal of Medicine DOI 10.1056/NEJMoa2108330 YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%
  2. 2021 Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer New England Journal of Medicine DOI 10.1056/NEJMoa2112435 YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%
  3. 2018 Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC New England Journal of Medicine DOI 10.1056/NEJMoa1809697 YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%
  4. 2017 Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer New England Journal of Medicine DOI 10.1056/NEJMoa1709937 YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%
  5. 2005 Multiple Myeloma New England Journal of Medicine DOI 10.1056/NEJM200502243520823 YÖKSİS SJR Q1 JCR Q1 OpenAlex 52.5%
  6. 2004 Uracil\u2013Tegafur in Early-Stage Lung Cancer New England Journal of Medicine DOI 10.1056/NEJM200408123510718 YÖKSİS SJR Q1 JCR Q1 OpenAlex 21.6%
  7. 2004 MRI in Breast Cancer New England Journal of Medicine DOI 10.1056/NEJM200411183512118 YÖKSİS SJR Q1 JCR Q1 OpenAlex 1.8%

← Back to academicians